Provides umbilical cord blood storage services to private subscribers. Offers cord blood testing and processing services for both private and donated samples. Now — the numbers.
This is an established company with proven profits.
Average growth of 7% a year over the last 4 years. Every year shown ended in profit.
If every debt were paid off today, $994.7M would still be left in the vault — a solid cushion for hard times.
The market pays 1.7× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 5 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 80% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
The net profit margin is 40% — still a thick cushion, though costs have been eating into it lately.
There is $994.7M in the vault; even if every debt were paid off, $994.7M would remain.
The stock sits at $0.95. Under exchange rules, stocks that stay below $1 for too long risk being removed from the market.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: earnings execution, the revenue breakdown.